argenx SE American Depositary Shares (ARGX) Stock
Key stats
- Market cap
- $61.48B
- Price / Earnings ratio
- 31.2x
- EPS (TTM)
- $31.67
- Volume
- Loading
- 52-week high
- $1072.75
- 52-week low
- $661.85
Source: third-party data provider, as of November 13, 2026
Recent news
argenx: 3 Key Takeaways for Long-Term Investors
argenx: 3 Key Takeaways for Long-Term Investors
ARGX
HRMY or ARGX: Which Is the Better Value Stock Right Now?
HRMY or ARGX: Which Is the Better Value Stock Right Now?
ARGX
What argenex (ARGX) Said on Its Q3 Earnings Call
What argenex (ARGX) Said on Its Q3 Earnings Call
ARGX
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
ARGXNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 63.69
- MACD 12/26/9
- 14.44
- EMA 9 of MACD
- 0.38
- MACD histogram
- 14.06
- SMA 50
- $927.23
- Price above SMA 50
- EMA 50
- $913.66
- Price above EMA 50
- SMA 200
- $859.04
- Price above SMA 200
- EMA 200
- $874.49
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
argenx: 3 Key Takeaways for Long-Term Investors
argenx: 3 Key Takeaways for Long-Term Investors
ARGXHRMY or ARGX: Which Is the Better Value Stock Right Now?
HRMY or ARGX: Which Is the Better Value Stock Right Now?
ARGXWhat argenex (ARGX) Said on Its Q3 Earnings Call
What argenex (ARGX) Said on Its Q3 Earnings Call
ARGXHALO Wins Court Order Blocking Merck's Keytruda SC in Europe
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
ARGX
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
ARGX
BMY or ARGX: Which Is the Better Value Stock Right Now?
BMY or ARGX: Which Is the Better Value Stock Right Now?
ARGX
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
ARGX
BMY vs. ARGX: Which Stock Is the Better Value Option?
BMY vs. ARGX: Which Stock Is the Better Value Option?
ARGX
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
ARGX
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
ARGXNews tone: automated (AI) classification of the article's content, not a price prediction.
About argenx SE American Depositary Shares
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 63.69
- MACD 12/26/9
- 14.44
- EMA 9 of MACD
- 0.38
- MACD histogram
- 14.06
- SMA 50
- $927.23
- Price above SMA 50
- EMA 50
- $913.66
- Price above EMA 50
- SMA 200
- $859.04
- Price above SMA 200
- EMA 200
- $874.49
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $861.00
- Average
- $1,153.86
- High
- $1,400.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.7 | +11.0 |
